HighPoint Advisor Group LLC Buys 601 Shares of Sanofi (NASDAQ:SNY)

HighPoint Advisor Group LLC raised its position in Sanofi (NASDAQ:SNY) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,985 shares of the company’s stock after buying an additional 601 shares during the period. HighPoint Advisor Group LLC’s holdings in Sanofi were worth $433,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Sanofi during the fourth quarter valued at $135,933,000. Boston Partners lifted its position in Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the period. Magnetar Financial LLC boosted its stake in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after purchasing an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC grew its position in shares of Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after buying an additional 664,455 shares during the period. Finally, Thrivent Financial for Lutherans lifted its holdings in Sanofi by 36.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after buying an additional 514,542 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

SNY opened at $53.95 on Thursday. The stock has a market cap of $136.92 billion, a P/E ratio of 21.67, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a fifty day simple moving average of $55.33 and a 200 day simple moving average of $52.74.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts expect that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target for the company. Three research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.